within Pharmacolibrary.Drugs.N_NervousSystem.N05B_Anxiolytics.N05BA05_PotassiumClorazepate;

model PotassiumClorazepate
  extends Pharmacolibrary.Drugs.ATC.N.N05BA05
  // parameters inherited from base class, duplicate, uncomment and change if necesarry
  /*
  
    weight         = 70,
    F              = 0.89,
    Cl             = 2.916666666666667e-07,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0014166666666666668,
    Tlag           = 600  
  */
  ;

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>PotassiumClorazepate</td></tr><tr><td>ATC code:</td><td>N05BA05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>15</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.015</td><td>L/kg/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Potassium clorazepate is a benzodiazepine prodrug used primarily as an anxiolytic, anticonvulsant, and for the management of alcohol withdrawal symptoms. It is converted in the body to its active metabolite nordiazepam (desmethyldiazepam). It is approved and used in several countries for anxiety disorders, epilepsy, and adjunct therapy in acute alcohol withdrawal.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after a single oral dose of 15 mg potassium clorazepate in healthy adult volunteers (mixed sex, age ~18-45 years).</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end PotassiumClorazepate;
